Show simple item record

dc.contributor.authorBundred, Nigel J
dc.contributor.authorAnderson, Elizabeth
dc.contributor.authorNicholson, Robert I
dc.contributor.authorDowsett, Mitch
dc.contributor.authorDixon, J Michael
dc.contributor.authorRobertson, John F R
dc.date.accessioned2009-10-05T14:25:58Z
dc.date.available2009-10-05T14:25:58Z
dc.date.issued2002
dc.identifier.citationFulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen., 22 (4):2317-9 Anticancer Res.en
dc.identifier.issn0250-7005
dc.identifier.pmid12174920
dc.identifier.urihttp://hdl.handle.net/10541/83559
dc.description.abstractBACKGROUND: This study was performed to determine whether drug action on breast tumours could also be analysed using a cell turnover index (CTI), a composite measurement of both proliferation and apoptosis. MATERIALS AND METHODS: Data were obtained from a randomized, placebo-controlled trial comparing three single doses (50, 125 and 250 mg) of intramuscular fulvestrant (Faslodex, previously known as ICI 182,780) with oral tamoxifen 20 mg/day for 14-21 days in women with early, operable, ER-positive breast cancer. CTI was calculated as the ratio of the proliferation index to the apoptotic index. RESULTS: Fulvestrant 250 mg significantly reduced CTI compared with both placebo (p = 0.0003) and tamoxifen (p = 0.026). The effect on CTI with tamoxifen was not significantly different from that with placebo. CONCLUSION: This study suggests that CTI may be a useful indicator of drug action on breast tumour growth. A significant reduction in growth was found with fulvestrant 250 mg compared with tamoxifen.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Receptor Modulatorsen
dc.subjectCultured Tumour Cellsen
dc.subject.meshAntineoplastic Agents
dc.subject.meshApoptosis
dc.subject.meshBreast Neoplasms
dc.subject.meshCell Division
dc.subject.meshEstradiol
dc.subject.meshEstrogen Receptor Modulators
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshKi-67 Antigen
dc.subject.meshKinetics
dc.subject.meshPlacebos
dc.subject.meshTamoxifen
dc.subject.meshTumor Cells, Cultured
dc.titleFulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, South Manchester University Hospital Education and Research Centre, UK. bundredn@man.ac.uken
dc.identifier.journalAnticancer Researchen
html.description.abstractBACKGROUND: This study was performed to determine whether drug action on breast tumours could also be analysed using a cell turnover index (CTI), a composite measurement of both proliferation and apoptosis. MATERIALS AND METHODS: Data were obtained from a randomized, placebo-controlled trial comparing three single doses (50, 125 and 250 mg) of intramuscular fulvestrant (Faslodex, previously known as ICI 182,780) with oral tamoxifen 20 mg/day for 14-21 days in women with early, operable, ER-positive breast cancer. CTI was calculated as the ratio of the proliferation index to the apoptotic index. RESULTS: Fulvestrant 250 mg significantly reduced CTI compared with both placebo (p = 0.0003) and tamoxifen (p = 0.026). The effect on CTI with tamoxifen was not significantly different from that with placebo. CONCLUSION: This study suggests that CTI may be a useful indicator of drug action on breast tumour growth. A significant reduction in growth was found with fulvestrant 250 mg compared with tamoxifen.


This item appears in the following Collection(s)

Show simple item record